Key stats
About SPDR S&P PHARMACEUTICALS ETF
Expense ratio
0.35%
Home page
Inception date
Jun 19, 2006
XPH offers equal-weighted exposure to a narrow selection of US pharmaceutical companies, stretching across all market caps. XPH's weighting scheme causes it to be far less concentrated than the industry, which is dominated by a handful of mega-cap names like J&J, Pfizer and Merck. The fund also introduces a heavy tilt to mid- and small-caps, which makes for a rather volatile fund relative to the industry. Overall, XPH is a solid way to capture a less concentrated version of the pharma market. The index is rebalanced quarterly.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.89%
Health Technology99.89%
Bonds, Cash & Other0.11%
Mutual fund0.11%
Stock breakdown by region
North America100.00%
Latin America0.00%
Europe0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history